Immunomodulatory Polypeptides Modulating TLR2 and TLR4 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis, cancer, organ transplantation, and autoimmune diseases face challenges in effectively modulating TLR2 and TLR4-mediated responses, leading to inadequate immunosuppression and increased risk of rejection or infection, with existing immunomodulators being either ineffective or immunogenic.
Innovation Solution
Development of short immunomodulatory polypeptides, such as those with the amino acid sequence KSIAYLQMNSLK or the general formula K-X1-X2-X3-YLQM-X4-X5-LK, that bind with low affinity to TLR2 and TLR4, interfering with signaling pathways to reduce inflammatory responses and promote immune regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunomodulators are used to treat sepsis and inflammatory conditions, then immunosuppressive effects are achieved, but the treatments are either ineffective or immunogenic
Solution Approach 1:
The patent changes the molecular parameters of the immunomodulator by using short peptide sequences (10-30 amino acids) with specific amino acid compositions and structures that bind to TLR2/TLR4. This parameter change from conventional large-molecule immunomodulators to optimized peptides resolves the contradiction by achieving effective immunomodulation while reducing immunogenicity through careful selection of amino acid sequences and molecular size.
2Reliability
If existing immunomodulators are used to prevent graft rejection, then immunosuppression is provided, but the risk of infection increases
Solution Approach 1:
The patent applies local quality by designing peptides with specific binding characteristics to TLR2/TLR4 that provide targeted immunomodulation. The peptides exhibit selective affinity for these specific receptors, allowing localized immune regulation at the site of infection or graft without systemically suppressing all immune functions, thus reducing infection risk while maintaining graft acceptance.
3Reliability
If TLR2/TLR4 signaling is strongly activated, then antimicrobial response is enhanced, but inflammatory damage increases
Solution Approach 1:
The patent applies partial action by using short peptides that provide moderate, controlled activation of TLR2/TLR4 signaling rather than strong activation. The peptide sequences are designed to elicit sufficient antimicrobial response while avoiding excessive inflammatory activation, achieving a balanced immune response that protects against pathogens without causing excessive tissue damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These polypeptides effectively moderate inflammatory cytokine profiles, reducing the severity of sepsis, graft rejection, and autoimmune disease symptoms while maintaining antimicrobial activity, and are non-immunogenic, making them suitable for human use.
Implementation Method 1
when engaged by appropriate ligands, mediate signal transduction that results in activation of downstream transcription factors
Data Source
AI summary
Disclosed are immunomodulatory polypeptides that behave as weak TLR2 and TLR4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine TLR2 and TLR4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.